Aurinia Pharmaceuticals
7298 Upper Clarenton Drive South
New Albany
OH
43054
United States
Tel: 3302839273
Website: http://www.auriniacareers.com/
37 articles with Aurinia Pharmaceuticals
-
Aurinia Pharmaceuticals to Present at Three Upcoming March 2021 Investor Conferences
3/2/2021
Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in multiple upcoming investor conferences
-
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
2/24/2021
- LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December 31, 2020 – - Conference call to be hosted today at 4:30 p.m. ET -
-
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/18/2021
Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET.
-
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
2/17/2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close.
-
The U.S. Food and Drug Administration gave the green light to Aurinia’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen for LN.
-
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
1/23/2021
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials
-
Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
1/23/2021
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
-
After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up. Here’s a look.
-
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
1/8/2021
Aurinia Pharmaceuticals Inc. announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner
-
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
12/17/2020
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments
-
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
12/15/2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.
-
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
12/2/2020
Aurinia Pharmaceuticals Inc. announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
-
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/20/2020
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted the newly appointed Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer, Stephen Robertson,
-
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
11/12/2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET. In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events” through the “I
-
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
11/10/2020
- U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 - - Conference call and webcast to be hosted today at 4:30pm EDT -
-
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
11/9/2020
- Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differentiation as a potential best-in-class CNI -
-
Clinical Catch-Up: November 2-6
11/9/2020
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look. -
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
-
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19
10/27/2020
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label exploratory trial evaluating the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with COVID-19 (SARS-CoV-2) – the VOCOVID study.
-
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020
10/22/2020
- Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic drug monitoring –